Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

OrganoidsFHeartbreak

Financiado

Organoids For Heartbreak

This project is a proof-of-concept study for organoid drug testing platform for disease modeling of cardiac fibrosis. I am going to develop a cardiac organoid on chip platform for disease modeling of cardiac fibrosis to identify t... ver más

31/08/2025

UMC UTRECHT

188K€

Presupuesto del proyecto: 188K€

Líder del proyecto

UNIVERSITAIR MEDISCH CENTRUM UTRECHT No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-04-11

HORIZON-MSCA-2022-PF-01-01: MSCA Postdoctoral Fellowships 2022 ExpectedOutcome:

I+D

Cerrada hace 2 años

0% 100% 100%

1 Participantes

UMC UTRECHT

187.62K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

RTC-2016-4957-1 INVESTIGACIÓN DE TERAPIAS ANGIOGÉNICAS BASADAS EN FACTOR TIS... 415K€ Cerrado

3DVasCMD Development of novel 3D vascularized cardiac models to inves... 1M€ Cerrado

BES-2013-063685 REGENERACION TISULAR, VASODILATACION ESPLACNICA Y BIOMARCADO... 84K€ Cerrado

FIBREX Targeting cardiac fibrosis with next generation RNA therapeu... 2M€ Cerrado

SAF2012-39947-C02-01 NANOLIBERACION DE MIRNA Y FIBROSIS RENAL 94K€ Cerrado

PID2021-122626OB-I00 ESTRATIFICACION DE FIBROBLASTOS CARDIACOS: ORIGEN Y SEGREGAC... 278K€ Cerrado

Duración del proyecto: 28 meses Fecha Inicio: 2023-04-11
Fecha Fin: 2025-08-31

Líder del proyecto

UNIVERSITAIR MEDISCH CENTRUM UTRECHT No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 188K€

Descripción del proyecto This project is a proof-of-concept study for organoid drug testing platform for disease modeling of cardiac fibrosis. I am going to develop a cardiac organoid on chip platform for disease modeling of cardiac fibrosis to identify the molecular mechanism of the pathologic interplay between endothelial cells, cardiomyocytes and cardiac fibroblasts, and its regulation by specific drug treatments. This model will be based on cardiac organoids previously developed at the host lab modified with endothelial cell component. Organoids with and without endothelial cells will be a tool for identification of endothelial contribution in cardiac fibrosis. Molecular mechanisms will be identified through selective interventions in known fibrotic pathways, with special focus on the Renin-Angiotensin-Aldosterone System. In addition, validity of this tool for drug testing will be established by proof-of-effect of known medications on fibrotic molecular phenotype and cardiac function. The platform will be designed as medium through-put for patient treatment optimization (precision medicine) and drug testing. Collectively, it has the potential to replace animal models in mechanistic research and drug development. The host lab is the perfect fit for this project. It has been on the forefront of cardiac organoid research and their previous work is the cornerstone for the cardiac organoid model used here. They possess the latest equipment for on-chip organoid cultivation and have extensive experience with augmentation and optimization of biopolymer hardness to simulate fibrotic environment. Additionally, Prof. Sluijter’s professional network of contacts and cooperation with local university spin-off companies provides the opportunity to investigate the interest of the industry in application of this project by scale-up of our drug testing platform for high through-put organoid drug screening platform.

Conecta tu I+D

Entra hoy

¿Olvide mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores